These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16797387)

  • 1. Serum myeloperoxidase and mortality in maintenance hemodialysis patients.
    Kalantar-Zadeh K; Brennan ML; Hazen SL
    Am J Kidney Dis; 2006 Jul; 48(1):59-68. PubMed ID: 16797387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients.
    Kalantar-Zadeh K; Kopple JD; Humphreys MH; Block G
    Nephrol Dial Transplant; 2004 Jun; 19(6):1507-19. PubMed ID: 15069177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients.
    Kalantar-Zadeh K; Kopple JD; Block G; Humphreys MH
    Am J Kidney Dis; 2001 Dec; 38(6):1251-63. PubMed ID: 11728958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress.
    Pupim LB; Himmelfarb J; McMonagle E; Shyr Y; Ikizler TA
    Kidney Int; 2004 Jun; 65(6):2371-9. PubMed ID: 15149350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients.
    Beberashvili I; Sinuani I; Azar A; Shapiro G; Feldman L; Stav K; Sandbank J; Averbukh Z
    Nutrition; 2015 Jan; 31(1):138-47. PubMed ID: 25466658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients.
    Stenvinkel P; Rodríguez-Ayala E; Massy ZA; Qureshi AR; Barany P; Fellström B; Heimburger O; Lindholm B; Alvestrand A
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):281-7. PubMed ID: 17699218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
    Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.
    Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA
    Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of ultrapure water on the levels of oxidative stress and inflammation parameters in maintenance hemodialysis patients].
    Zhang Y; Liu J; Tao HQ; Liu ZQ; Tian JW
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1435-7. PubMed ID: 17884796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation.
    Rambod M; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1691-701. PubMed ID: 18922994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nutritional status, comorbidity, and inflammation in hemodialysis].
    Fernández-Reyes MJ; Alvarez-Ude F; Sánchez R; Mon C; Iglesias P; Vázquez A
    Nefrologia; 2000; 20(6):540-9. PubMed ID: 11217649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White blood cell count predicts all-cause, cardiovascular disease-cause and infection-cause one-year mortality of maintenance hemodialysis patients.
    Hsu CW; Lin JL; Lin-Tan DT; Yen TH; Chen KH
    Ther Apher Dial; 2010 Dec; 14(6):552-9. PubMed ID: 21118362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metabolic disturbances and malnutrition-inflammation on 6-year mortality in Japanese patients undergoing hemodialysis.
    Nakagawa N; Matsuki M; Yao N; Hirayama T; Ishida H; Kikuchi K; Hasebe N
    Ther Apher Dial; 2015 Feb; 19(1):30-9. PubMed ID: 25196142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.
    Heslop CL; Frohlich JJ; Hill JS
    J Am Coll Cardiol; 2010 Mar; 55(11):1102-9. PubMed ID: 20223364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis.
    Al-Hweish A; Sultan SS; Mogazi K; Elsammak MY
    Hemodial Int; 2010 Jul; 14(3):308-15. PubMed ID: 20597992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of plasma myeloperoxidase in ESRD patients.
    Wang AY; Lam CW; Chan IH; Wang M; Lui SF; Sanderson JE
    Am J Kidney Dis; 2010 Nov; 56(5):937-46. PubMed ID: 20638167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease.
    Stefanescu A; Braun S; Ndrepepa G; Koppara T; Pavaci H; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2008 Feb; 155(2):356-60. PubMed ID: 18215608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloperoxidase and C-reactive protein in patients with cocaine-associated chest pain.
    O'Conor K; Chang AM; Wu AH; Hollander JE
    Am J Emerg Med; 2013 Apr; 31(4):664-9. PubMed ID: 23380098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal disease.
    Kitabayashi C; Naruko T; Sugioka K; Yunoki K; Nakagawa M; Inaba M; Ohsawa M; Konishi Y; Imanishi M; Inoue T; Itabe H; Yoshiyama M; Haze K; Becker AE; Ueda M
    Hemodial Int; 2013 Oct; 17(4):557-67. PubMed ID: 23627905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients.
    Kaysen GA; Levin NW; Mitch WE; Chapman AL; Kubala L; Eiserich JP
    Blood Purif; 2006; 24(5-6):508-16. PubMed ID: 17077623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.